Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Unlabelled: Several randomized controlled trials (RCTs) comparing en bloc resection of bladder tumor (ERBT) to conventional transurethral resection of bladder tumor (cTURBT) have reported controversial results. In particular, the 1-yr recurrence rate ranged from 5% to 40% for ERBT and from 11% to 31% for cTURBT. We provide an updated analysis of an RCT comparing the 1-yr recurrence rate for ERBT versus cTURBT for a cohort of 219 patients comprising 123 (56.2%) in the ERBT group and 96 (43.8%) in the cTURBT group. At 1 yr, 11 patients in the ERBT group and 12 in the cTURBT group experienced recurrence. The heterogeneity in recurrence observed in other RCTs could be explained by the scarce and heterogeneous adoption of tools and techniques that have been proved to lower the recurrence rate, supporting the need for implementation of a TURBT checklist. This prompted us to create a checklist of items for RCTs to standardize how TURBT is performed in trials, facilitate comparison between studies, assess the applicability of results in real-life practice, and provide a push towards high-quality resections to improve oncological outcomes. The checklist could have utility as a user-friendly guide for reporting TURBT procedures to improve our understanding of trials involving this procedure.

Patient Summary: We compared the recurrence rate at 1 year for bladder cancer treated with two different approaches to remove bladder tumors in our center. The rates were comparable for the two groups. Other studies have found widely differing recurrence rates, so we propose use of a checklist to standardize these procedures and provide more consistent outcomes for patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795511PMC
http://dx.doi.org/10.1016/j.euros.2022.09.025DOI Listing

Publication Analysis

Top Keywords

recurrence rate
16
resection bladder
12
bladder tumor
12
transurethral resection
8
oncological outcomes
8
1-yr recurrence
8
erbt group
8
cturbt group
8
recurrence
7
bladder
5

Similar Publications

ObjectiveRandomized trials will ultimately determine whether stand-alone middle meningeal artery embolization (MMAE) is effective in preventing the recurrence of chronic subdural hematoma (cSDH). We therefore characterized in-hospital complications, length of stay, and discharge disposition among adults undergoing stand-alone MMAE for non-traumatic cSDH in the United States.MethodsWe conducted a retrospective cohort analysis using the National Inpatient Sample (2016-2022) to identify adult patients (≥18 years) with a primary diagnosis of nontraumatic cSDH.

View Article and Find Full Text PDF

Place of Death of Cancer Patients Treated at a German Comprehensive Cancer Center.

Palliat Med Rep

May 2025

Department of Palliative Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Comprehensive Cancer Centres, CCC Erlangen-EMN, Comprehensive Cancer Centres Alliance WERA (CCC WERA), Bavarian Cancer Research Centres (BZKF), Erlangen, Germany.

Background: Public health research includes end-of-life care. Place of death is an indicator of end-of-life care quality.

Objective: We assessed the place of death of cancer patients treated at a Comprehensive Cancer Center (CCC), caring for an average of 2220 primary cases per year.

View Article and Find Full Text PDF

Background: Neoantigen-based vaccines show promising therapeutic potential in solid tumors such as melanoma, GBM, NSCLC, and CRC. However, clinical responses remain suboptimal in stage IV patients, due to ineffective T-cell function and high tumor burdens. To overcome these limitations, our study investigates a combination strategy using neoantigen peptide vaccines and precision critical lesion radiotherapy (CLERT), which delivers immunomodulatory doses to key tumor regions synergistically enhance immune activation and inhibit progression in multifocal stage IV patients.

View Article and Find Full Text PDF

Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.

iScience

September 2025

Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, No.10 Xitoutiao You'anmenwai Fengtai District, Beijing 100069, P.R. China.

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, and EGFRvIII mutation has been associated with treatment resistance and poor prognosis, highlighting the need for more effective therapeutic strategies. We conducted a random-effects Bayesian network meta-analysis to compare the efficacy and safety of treatments for EGFRvIII-positive recurrent GBM (rGBM), evaluating overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Seven clinical trials were included ( = 716).

View Article and Find Full Text PDF

Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non-small cell lung cancer.

Oncol Lett

November 2025

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China.

Neoadjuvant chemotherapy combined with immunotherapy is a crucial treatment modality for patients with resectable non-small cell lung cancer (NSCLC). Whilst neoadjuvant chemoimmunotherapy enables tumor downstaging, the impact of reducing the surgical scope (such as from pneumonectomy to lobectomy) on safety and efficacy remains unvalidated in real-world settings. The present study aimed to use real-world data to compare the safety and long-term efficacy of several surgical methods following neoadjuvant treatment.

View Article and Find Full Text PDF